Relief Therapeutics Holding AG

Relief Therapeutics Holding AG is a Swiss-based pharmaceutical company specializing in the research, development, and commercialization of drug products. Its primary focus is on providing solutions for rare and debilitating diseases, particularly emphasizing respiratory and inflammatory conditions. A key feature of Relief Therapeutics' portfolio is its therapeutic candidate RLF-100, targeting acute respiratory distress syndromes and other severe lung-related conditions. The company's research primarily impacts the biopharmaceutical and healthcare sectors, where there is a critical need for innovative treatments addressing unmet medical needs. Relief Therapeutics plays a significant role in the pharmaceutical market by advancing therapies that may enhance patient outcomes, especially in niche medical areas with few available treatment options.